Take-home naloxone program

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Retrieved on: 
Monday, November 20, 2023
Principal, Safety, Johns Hopkins, MIRA, DSM-IV codes, Hope, CSA, Chairperson, Controlled Substances Act, FDA, Depression, National Network, MD, Partnership, TRD, DEA, Doctor of Philosophy, Suicidal ideation, Mental health, Take-home naloxone program, MDSI, Schedule, Pharmaceutical industry, Ketamine, Esketamine

BALTIMORE, Nov. 20, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.

Key Points: 
  • Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
  • This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.
  • Unlike Ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, in initial pre-clinical studies, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.
  • The combination of this exclusive licensing agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation and development."

TAKING ON THE OPIOID OVERDOSE EPIDEMIC IN NEW JERSEY

Retrieved on: 
Thursday, August 3, 2023
State, Partnership, Hackensack Meridian Health, Drug overdose, Naloxone, Friends, United States drug overdose death rates and totals over time, South Carolina Opioid Overdose Prevention Bill, Dispensary, Naugle v. Philip Morris USA, Inc., Mortality, Heroin, Marketing, Opioid epidemic, Jersey Shore University Medical Center, CDC, Organization, Death, School, Addiction medicine, HMH, Take-home naloxone program, Harm Reduction Journal, Patient, Drug, Risk, Health, Hikma Pharmaceuticals, Hospital, Pharmaceutical industry, Silviculture, Fentanyl, Lancet

HACKENSACK, N.J., Aug. 3, 2023 /PRNewswire/ -- HIKMA Pharmaceuticals, Hackensack Meridian Health (HMH) and non-profit Dispensary of Hope are teaming up to pilot a Take-Home Naloxone Program to stem the tide of opioid overdose fatalities by delivering Kloxxado® (naloxone HCl) Nasal Spray 8 mg free of charge to patients at high risk of an opioid overdose. Kloxxado® contains naloxone, an opioid antagonist that can save the lives of patients who have overdosed with an opioid.1 All three organizations share a vision of providing affordable medication access, with a particular focus on communities and individuals who are most vulnerable.

Key Points: 
  • Hackensack Meridian Health, HIKMA Pharmaceuticals and Dispensary of Hope join forces to save lives from opioid overdose.
  • Opioid overdoses are preventable and tragic.
  • 2022, "Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission," The Lancet,  399:10324, p555-604
    3 Opioid Basics: Understanding the Opioid Epidemic.
  • CDC, https://www.cdc.gov/stopoverdose/fentanyl/index.html , Accessed 2022 1006
    6 Abdelal et al., 2022, "Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders," Harm Reduction Journal, 19:49.

CAO Group Launches The World's First In-Office And Take Home Teeth Whitening Strip System

Retrieved on: 
Thursday, November 18, 2021
Patient, Dental Materials, Patient satisfaction, Hygiene, CEO, Sheer, Time, Salt Lake, Hydrogen peroxide, Take-home naloxone program, SALT, LED, Doctor of Philosophy, Solution, White, CAO, Radioactive decay, Multimedia, Method, Dentistry

SALT LAKE CITY, Nov. 18, 2021 /PRNewswire/ -- The CAO Group, Inc. (CAO), a world leading high-technology dental company, has launched the world's first in office and take home teeth whitening strip system for dental practices, SheerWhite In-Office Teeth Whitening Strips and SheerWhite Take Home Teeth Whitening Strips.

Key Points: 
  • SALT LAKE CITY, Nov. 18, 2021 /PRNewswire/ -- The CAO Group, Inc. (CAO), a world leading high-technology dental company, has launched the world's first in office and take home teeth whitening strip system for dental practices, SheerWhite In-Office Teeth Whitening Strips and SheerWhite Take Home Teeth Whitening Strips.
  • Sheer White In-Office Teeth Whitening Strips contain 20% hydrogen peroxide to deliver immediate professional teeth whitening results with minimal time and effort for both the dental practice and their patients.
  • To continue whitening the teeth, a SheerWhite Take Home Teeth Whitening Strip kit can be provided to the patient to enhance their in-office whitening treatment at home.
  • "The SheerWhite In-Office and Take Home Whitening Strip System will make whitening through the dental practice Easier, Faster, and Better. "